Rapha Capital Management
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Rapha Capital Management.
Key people at Rapha Capital Management.
Key people at Rapha Capital Management.
Rapha Capital Management is a venture capital firm specializing in early-stage investments in medicine, healthcare, and biotechnology. Their mission centers on identifying and nurturing revolutionary ideas in these sectors before they gain widespread recognition, focusing on potentially disruptive biopharmaceutical companies and innovative healthcare technologies. This proactive approach allows them to support startups that address critical medical challenges and advance therapeutic solutions, thereby impacting the broader startup ecosystem by accelerating innovation in life sciences and healthcare technology[1][2][4].
Founded in 2018 and based in Surfside, Florida, Rapha Capital Management was established by Dr. Kevin Slawin, a pioneer in robotic prostatectomy and a successful biotech entrepreneur. Dr. Slawin’s background includes founding Bellicum Pharmaceuticals, which developed controllable cellular immunotherapy and went public in 2014, marking a significant milestone in cancer treatment innovation. His experience with breakthrough medical technologies and startups informs Rapha’s investment philosophy. The firm has evolved to focus on early-stage companies with transformative potential in medicine and biotech, leveraging Dr. Slawin’s expertise and network to identify promising ventures[4][5].
Rapha Capital Management rides the wave of rapid advancements in biotechnology, immunotherapy, and healthcare innovation, sectors experiencing accelerated growth due to aging populations, rising chronic diseases, and technological breakthroughs. The timing is critical as new therapies like CAR T-cell treatments and precision medicine reshape clinical care. By investing early in these transformative technologies, Rapha influences the ecosystem by enabling startups to overcome funding gaps and technical challenges, thus fostering a pipeline of next-generation medical solutions that could redefine patient outcomes and healthcare delivery[2][4].
Looking ahead, Rapha Capital Management is poised to deepen its impact by continuing to back pioneering biotech and healthcare startups, especially those leveraging novel cellular therapies and high-throughput screening technologies. Trends such as personalized medicine, anti-aging therapeutics, and AI-driven drug discovery will likely shape their investment focus. With Dr. Slawin’s ongoing involvement in innovative ventures like Ponce Therapeutics and DELiver Therapeutics, Rapha is expected to maintain a leadership role in translating cutting-edge science into commercial success, further influencing the life sciences investment landscape[4].
This forward-looking vision ties back to Rapha’s core mission of identifying revolutionary ideas early and nurturing them to transform medicine and healthcare.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2024 | CereVasc | $70.0M Series B | — | Perceptive Advisors |
| Apr 1, 2021 | FIZE Medical | $5.0M Series A | — | Perceptive Advisors |
| Jun 1, 2020 | CereVasc | $44.0M Series A | — | Perceptive Advisors |
| Jun 1, 2020 | AsclepiX Therapeutics | $35.0M Series A | — | Perceptive Advisors |
